ENOS gene influences platelet phenotype in acute coronary syndrome patients on dual antiplatelet treatment

Platelets

Volumn 20, Issue 8, 2009, Pages 548-554

  Fatini, Cinzia ^a,b   Sticchi, Elena ^a,b   Bolli, Paola ^a,b,c   Marcucci, Rossella ^a,b   Giusti, Betti ^a,b   Paniccia, Rita ^a,b   Gori, Anna Maria ^a,b   Gensini, Gian Franco ^a,b,c   Abbate, Rosanna ^a,b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Acute coronary syndrome; ENOS gene polymorphisms; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; NITRIC OXIDE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ARTICLE; ENOS GENE; FEMALE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS;

EID: 73649140577     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537100903337401     Document Type: Article

References (31)

1. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990;87:5193-5197.
2. Gambarayan S, Kobsar A, Hartmann S, Birschmann I, Kuhlencordt PJ, Mü ller-Esterl W, Lohmann SM, Walter U. NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost 2008;6:1376-1384.
3. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, Dangas G, Taniuchi M, Lasala JM, Holmes DR, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14.
4. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997;100:350-356.
5. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney Jr JF, Vita JA. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998;98:1481-1486.
6. Kim IJ, Bae J, Lim SW, Cha DH, Cho HJ, Kim S, Yang DH, Hwang SG, Oh D, Kim NK. Influence of endothelial nitric oxide synthase gene polymorphisms (-786T4C, 4a4b, 894G4T) in Korean patients with coronary artery disease. Thromb Res 2007;119:579-585.
7. Ciftçi C, Melil S, Cebi Y, Ersöz M, Cagatay P, Kiliçgedik M, Duman BS. Association of endothelial nitric oxide synthase promoter region (T-786C) gene polymorphism with acute coronary syndrome and coronary heart disease. Lipids Health Dis 2008;7:5.
8. Fatini C, Sofi F, Sticchi E, Gensini F, Gori AM, Fedi S, Lapini I, Rostagno C, Comeglio M, Brogi D, et al. Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes. Am Heart J 2004;147:516-521.
9. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
10. Snoep JD, Hovens MM, Eikenboom JC, Van Der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 2007;167:1593-1599.
11. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events - A meta-analysis. Int J Cardiol 2008;128:166-171.
12. Madajka M, Korda M, White J, Malinski T. Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Thromb Res 2003;110:317-321.
13. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, Tschentscher P, Meinertz T, Böger R, Baldus S. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: Evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006;26:1648-1652.
14. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007;17:1057-1064.
15. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317.
16. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up. Circulation 2009;119:237-242.
17. Paniccia R, Antonucci E, Gori AM, Marcucci R, Poli S, Romano E, Valente S, Giglioli C, Fedi S, Gensini GF, et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 2007;128:143-149.
18. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965.
19. Sticchi E, Lenti M, Giusti B, Sestini I, Abbate R, Fatini C. LPA+93C4T and +121G4A polymorphisms detection by electronic microchip technology. Mol Genet Metab 2007;91:79-84.
20. Marcucci R, Gori AM, Paniccia R, Giglioli C, Buonamici P, Antoniucci D, Gensini GF, Abbate R. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis 2007;195: e217-223.
21. Bolli P, Sticchi E, Abbate R, Fatini C. A novel allele of eNOS gene in the Italian population: The actual essence of intron 4 polymorphism. Nitric Oxide 2007;16:392-394.
22. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, De Leeuw PW, Smits P. The Glu298Asp polymorphisms of the NOS3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002;20: 2023-2027.
23. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, et al. T-786C mutation in the 50-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999;99: 2864-2870.
24. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T, Igari J. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998;245:190-193.
25. Dosenko VE, Zagoriy VY, Haytovich NV, et al. Allelic polymorphism of endothelial NO-synthase gene and its functional manifestations. Acta Biochim Pol 2006;53: 299-302.
26. Matsuoka I, Nakahata N, Nakanishi H. Inhibitory effect of 8-bromo cyclic GMP on an extracellular Ca2+-dependent arachidonic acid liberation in collagen-stimulated rabbit platelets. Biochem Pharmacol 1989;38:1841-1847.
27. Wang GR, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMPdependent protein kinase. Proc Natl Acad Sci U S A 1998;95:4888-4893.
28. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, Hofmann F, Du X. A stimulatory role for cGMPdependent protein kinase in platelet activation. Cell 2003;112:77-86.
29. Morrell CN, Matsushita K, Chiles K, Scharpf RB, Yamakuchi M, Mason RJ, Bergmeier W, Mankowski JL, Baldwin WM 3rd, Faraday N, et al. Regulation of platelet granule exocytosis by S-nitrosylation. Proc Natl Acad Sci U S A 2005;102:3782-3787.
30. Malinski T, Radomski MW, Taha Z, Moncada S. Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun 1993;194:960-965.
31. Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA, Freedman JE. Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 2002;12:407-413.